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Abstract: Pseudomonas aeruginosa is an opportunistic human pathogen associated with cystic 
fibrosis. This bacterium produces, among other virulence factors, a soluble D-galactose-specific 
lectin PA-IL (LecA). PA-IL plays an important role in the adhesion to the host cells and is also 
cytotoxic. Therefore, this protein is an interesting therapeutic target, suitable for inhibition by 
carbohydrate-based compounds. In the current study, β-D-galactopyranoside-containing tri- and 
tetravalent glycoclusters were synthesized. Methyl gallate and pentaerythritol equipped with 
propargyl groups were chosen as multivalent scaffolds and the galactoclusters were built from the 
above-mentioned cores by coupling ethylene or tetraethylene glycol-bridges and peracetylated 
propargyl β-D-galactosides using 1,3-dipolar azide-alkyne cycloaddition. The interaction between 
galactoside derivatives and PA-IL was investigated by several biophysical methods, including 
hemagglutination inhibition assay, isothermal titration calorimetry, analytical ultracentrifugation, 
and surface plasmon resonance. Their ability to inhibit the adhesion of P. aeruginosa to bronchial 
cells was determined by ex vivo assay. The newly synthesized multivalent galactoclusters proved 
to be significantly better ligands than simple D-galactose for lectin PA-IL and as a result, two 
representatives of the dendrimers were able to decrease adhesion of P. aeruginosa to bronchial cells 
to approximately 32% and 42%, respectively. The results may provide an opportunity to develop 
anti-adhesion therapy for the treatment of P. aeruginosa infection. 
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1. Introduction 
Lectins are specific carbohydrate-binding proteins of a non-immune origin. Lectins from the 
pathogens could be important virulence factors involved in recognition and adhesion processes 
between pathogens and hosts [1]. Therefore, lectins are promising therapeutic targets which could be 
inhibited by carbohydrate-based inhibitors [2]. Lectins are usually multivalent proteins, containing 
several binding sites per molecule and/or forming oligomers. They frequently display an avidity 
effect, resulting in significantly increased affinity towards glycosylated surfaces. Consequently, the 
multivalent compounds with multiple carbohydrate moieties available are considered to be a 
possible method to efficiently inhibit lectins [3]. 
The Gram-negative bacterium Pseudomonas aeruginosa is an important opportunistic pathogen 
causing lung infections in immunocompromised individuals, especially cystic fibrosis patients. It is 
the most common pathogen associated with this hereditary disease [4]. P. aeruginosa produces soluble 
D-galactose-specific lectin PA-IL (LecA) [5,6]. PA-IL is a tetrameric calcium-dependent lectin with one 
binding site per monomer. Each binding site contains one calcium ion directly involved in the 
carbohydrate recognition and binding [7]. PA-IL is considered to be a significant virulence factor [8]. 
In addition to its supposed primary role as an adhesin, the lectin is involved in the biofilm formation 
[9] and is cytotoxic. Specifically, PA-IL displayed toxicity to respiratory epithelial cells in primary 
culture [10]. Due to its importance, several types of multivalent inhibitors were designed and tested 
against PA-IL, including fullerene-based glycoclusters [11], glycodendrimers [12], glycopeptide 
dendrimers [13], resorcin[4]arene-based glycoclusters [14], inhibitors based on porphyrin scaffold 
and β-peptoids [15], glycosylated poly(phenylacetylene)s [16], glycoconjugates based on a 
calix[4]arene scaffold [17,18] and on a pentaerythritol core [19]. Furthermore, the D-galactose surface-
modified polymeric nanoparticles [20] and glycodendrimer micelles [21] were prepared. 
In many cases, the efficiency of multivalent carbohydrate-based inhibitors is based on the chelate 
effect—the intramolecular binding of multivalent ligand to several binding sites of lectin. However, 
the multivalent inhibitors can also cross-link lectin molecules by intermolecular binding, possibly 
resulting in the formation of large aggregates and subsequent precipitation of the complexes [22]. 
Considering PA-IL, it was suggested that tetravalent inhibitors capable of lectin cross-linking are the 
most suitable for the inhibition of Pseudomonas aeruginosa biofilm formation [23]. The ability of 
multivalent compounds to cross-link lectins can also lead to cross-linking and aggregation of bacteria 
cells presenting these lectins on their surfaces [18,24,25]. This aggregation can serve as proof that 
inhibitors are able to interact with native lectins on the cells surfaces; however, it can also interfere 
with biofilm formation. A negative correlation to biofilm formation was observed for the aggregation 
of Pseudomonas aeruginosa cells [26]. 
In the current paper, we describe the efficient synthesis of β-D-galactopyranoside-presenting 
oligovalent glycoclusters and their testing as inhibitors of the lectin PA-IL. Their inhibitory potency 
was determined by hemagglutination inhibition assay and surface plasmon resonance. Interactions 
were characterized using isothermal titration calorimetry and the cross-linking ability was examined 
by analytical ultracentrifugation and experiments with whole Pseudomonas aeruginosa cells. Selected 
compounds were further tested for their ability to inhibit the adhesion of P. aeruginosa to epithelial 
bronchial cells derived from a cystic fibrosis patient in an ex vivo assay.  
2. Materials and Methods  
2.1. General Methods 
Optical rotations were measured at room temperature with a Perkin-Elmer 241 automatic 
polarimeter (PerkinElmer, Waltham, MA, USA). TLC analysis was performed on Kieselgel 60 F254 
silica gel plates (Merck, Kenilworth, NJ, USA) with visualization by immersing in a sulfuric-acid 
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solution (5% in EtOH, VWR International Ltd., Radnor, PA, USA) followed by heating. Column 
chromatography was performed on silica gel 60 (Merck 0.063–0.200 mm) and flash column 
chromatography was performed on silica gel 60 (Merck 0.040–0.063 mm). Gel filtration was 
performed on Sephadex G-25 using methanol as the eluent. Organic solutions were dried over MgSO4 
and concentrated under vacuum. The 1H (400 and 500 MHz) and 13C NMR (100.28, 125.76 MHz) 
spectra were recorded with Bruker DRX-400 and Bruker Avance II 500 spectrometers (Billerica, MA, 
USA). Chemical shifts are referenced to Me4Si or DSS (0.00 ppm for 1H) and to solvent signals (CDCl3: 
77.00 ppm, CD3OD: 49.15 ppm for 13C). MS (MALDI-TOF) analysis was carried out in positive 
reflectron mode with a BIFLEX III mass spectrometer (Billerica, MA, USA) with delayed-ion 
extraction. The matrix solution was a saturated solution of 2,4,6-trihydroxy-acetophenone (THAP) in 
CH3CN. 
2.2. Synthesis 
2.2.1. General Method A for Azide-Alkyne Click Reaction 
Et3N (1 equiv./alkyne) and Cu(I)I (0.1 equiv./alkyne) were added to a stirred solution of alkyne 
(1.5 equiv/azide moiety) and azide in CH3CN under an argon atmosphere and stirred overnight at 
room temperature. The reaction mixture was evaporated and the crude product was purified by flash 
column chromatography to give the desired compound. 
2.2.2. General Method B for Zemplén-Deacetylation 
A catalytic amount of NaOMe (pH = 9) was added to a stirred solution of ester (0.2 mmol) in dry 
MeOH (5 mL) and stirred overnight at room temperature. The reaction mixture was neutralized with 
Amberlite IR-120 H+ ion-exchange resin, filtered and evaporated, then the crude product was purified 
by flash column chromatography and gel filtration to give the desired compound. 
2.2.3. Compound 3  
Azide compound 1 (100 mg, 0.10 mmol) and alkyne 2 (169 mg, 0.44 mmol) were reacted in 
CH3CN according to the general method A. The crude product was purified by flash column 
chromatography (95:5 CH2Cl2:MeOH) to give compound 3 (118 mg, 55%) as a colourless syrup. [α]24D 
–21.96 (c 0.46, CHCl3); Rf 0.33 (95:5 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3): δ = 7.94, 7.90, 7.72 (3 
x s, 6H, 6 x CH triazole), 7.44 (s, 2H, arom), 5.40 (d, J = 2.9 Hz, 3H, skeleton proton), 5.23 (s, 6H, 3 x 
CH2), 5.20–5.18 (m, 3H, 3 x skeleton protons), 5.02 (dd, J = 3.4 Hz, J = 10.4 Hz, 3H, 3 x skeleton protons), 
4.94 (d, J = 12.5 Hz, 3H, 3 x H-6a), 4.80 (d, J = 12.5 Hz, 3H, 3 x H-6b), 4.68 (d, J = 7.9 Hz, 3H, 3 x H-1), 
4.59–4.50 (m, 11H, 3 x H-5, 4 x CH2), 4.18–4.15 (m, 6H, 3 x CH2), 3.99–3.84 (m, 19H, 8 x CH2, COOCH3), 
3.61-3.55 (m, 24H, 12 x CH2), 2.15, 2.06, 1.97 (3 x s, 36H, 12 x CH3 acetyl) ppm; 13C NMR (100 MHz, 
CDCl3) δ = 170.4, 170.2, 170.1, 169.5 (12C, 12 x CO acetyl), 166.3 (1C, COOCH3), 152.0 (2C, 2 x Cq arom), 
144.0, 148.8, 143.1, 141.6 (6C, 6 x Cq triazole), 125.7 (2C, 2 x Cq arom), 124.9, 124.5, 124.0 (6C, 6 x CH 
triazole), 109.2 (2C, arom), 100.3, 100.2 (3C, 3 x C-1), 70.9, 70.8, 68.8, 67.1 (12C, 3 x skeleton carbons), 
70.5, 70.4, 69.3 (18C, 18 x CH2 TEG), 63.0, 62.8, 62.7 (3C, 3 x C-6), 61.3 (6C, 6 x CH2 propargyl), 52.4 
(1C, COOCH3), 50.3, 50.2, 50.1 (6C, 6 x NCH2 TEG), 20.7, 20.6 (12C, 12 x CH3 acetyl) ppm; MALDI-
TOF (positive ion): m/z calcd for C92H128N18NaO44: 2211.82 [M + Na]+ Found: 2211.78. 
2.2.4. Compound 4  
Compound 3 (86 mg, 0.04 mmol) was deacetylated according to general method B. The crude 
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 4 (48 
mg, 73%) as a colourless syrup. [α]24D—6.4 (c 0.14, MeOH); Rf 0.34 (7:3 CH3CN:H2O); 1H NMR (400 
MHz, D2O): δ = 8.00, 7.92, 7.73 (3 x s, 6H, 6 x CH triazole), 7.29 (s, 2H, arom), 5.08 (s, 4H, 2 x CH2 
propargyl), 5.01 (s, 2H, CH2 propargyl), 4.84-4.65 (m, 6H, 3 x CH2 propargyl), 4.51-4.38 (m, 12H, 6 x 
NCH2 TEG), 4.34 (d, J = 7.7 Hz, 3H, 3 x H-1), 3.81–3.70 (m, 22H, 3 x H-4, COOCH3, 8 x OCH2 TEG), 
3.69-3.61 (m, 6H, 3 x H-6a,b), 3.56 (dd, J = 4.4 Hz, J = 7.5 Hz, 3H, 3 x H-5), 3.50 (dd, J = 3.4 Hz, J = 9.9 
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Hz, 3H, 3 x H-3), 3.44–3.32 (m, 23H, 3 x H-2, 10 x OCH2 TEG) ppm; 13C NMR (100 MHz, D2O) δ = 168.7 
(1C, COOCH3), 152.4 (2C, 2 x Cq arom), 144.6, 143.8, 141.3 (6C, 6 x Cq triazole), 126.7, 126.4 (6C, 6 x 
CH triazole), 126.5 (2C, 2 x Cq arom), 110.1 (2C, arom), 103.0 (3C, 3 x C-1), 76.2 (3C, 3 x C-5), 73.8 (3C, 
3 x C-3), 71.6 (3C, 3 x C-2), 70.7, 70.6, 70.4, 70.0, 69.6 (18C, 18 x CH2 TEG), 69.5 (3C, 3 x C-4), 66.0, 62.9 
61.7 (6C, 6 x CH2 propargyl), 61.9 (3C, 3 x C-6), 53.9 (1C, COOCH3), 51.1, 51.0, 50.9 (6C, 6 x NCH2 TEG) 
ppm; MALDI-TOF (positive ion): m/z calcd for C68H104N18NaO32: 1707.70 [M + Na]+ Found: 1707.65. 
2.2.5. Compound 6  
Azide compound 5 (85 mg, 0.05 mmol) and alkyne 2 (111 mg, 0.29 mmol) were reacted in CH3CN 
according to general method A. The crude product was purified by flash column chromatography 
(95:5 CH2Cl2:MeOH) to give compound 6 (79 mg, 42%) as a colourless syrup. [α]24D—16.9 (c 0.13, 
CHCl3); Rf 0.38 (95:5 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3) δ = 7.73, 7.72 (2 x s, 8H, 8 x CH 
triazole), 5.40 (d, J = 2.8 Hz, 4H, 4 x H-4), 5.20 (dd, J = 8.0 Hz, J = 10.4 Hz, 4H, 4 x H-2), 5.02 (dd, J = 3.4 
Hz, J = 10.4 Hz, 4H, 4 x H-3), 4.95 (d, J = 12.5 Hz, 4H, 4 x CH2a), 4.80 (d, J = 12.5 Hz, 4H, 4 x CH2b), 4.68 
(d, J = 8.0 Hz, 4H, 4 x H-1), 4.58–4.53 (m, 20H, 8 x CH2 propargyl, 2 x CH2 TEG), 4.19–4.15 (m, 8H, 4 x 
H-6a,b), 3.99-3.94 (m, 4H, 4 x H-5), 3.90-3.86 (m, 20H, 10 x CH2 TEG), 3.62-3.58 (m, 32H, 16 x CH2 
TEG), 3.46 (s, 8H, 4 x CH2 pentaerythritol), 2.15, 2.06, 1.98, 1.97 (4 x s, 48H, 16 x CH3 acetyl) ppm; 13C 
NMR (100 MHz, CDCl3) δ = 170.4, 170.2, 170.1, 169.5 (16C, 16 x CO acetyl), 145.0, 143.9 (8C, Cq 
triazole), 124.0, 123.7 (8C, CH triazole), 100.3 (4C, 4 x C-1), 70.9, 70.8, 68.8, 67.1 (16C, 4 x skeleton 
carbons), 70.5, 70.4, 69.4, 69.3, 69.1 (28C, 24 x OCH2 TEG, 4 x CH2 pentaerythritol), 64.9 (4C, 4 x CH2 
propargyl), 62.8 (4C, 4 x C-6), 61.3 (4C, 4 x CH2 propargyl), 50.3, 50.1 (8C, 8 x NCH2 TEG), 45.3 (1C, 
Cq pentaerythritol), 20.7, 20.6, 20.5 (16C, 16 x CH3 acetyl) ppm;MALDI-TOF (positive ion): m/z calcd 
for C117H172N24NaO56: 2832.12 [M + Na]+ Found: 2832.15. 
2.2.6. Compound 7  
Compound 6 (78 mg, 0.28 mmol) was deacetylated according to general method B. The crude 
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 7 (44 
mg, 73%) as a colourless syrup. [α]24D—2.5 (c 0.12, MeOH); Rf 0.15 (7:3 CH3CN:H2O); 1H NMR (400 
MHz, D2O) δ = 7.95, 7.89 (2 x s, 8H, 8 x CH triazole), 4.85-4.66 (m, 16H, 8 x CH2 propargyl), 4.45–4.44 
(m, 16H, 4 x NCH2 TEG), 4.32 (d, J = 7.6 Hz, 4H, 4 x H-1), 3.80-3.77 (m, 20H, 4 x C-4, 8 x CH2 TEG), 
3.68-3.59 (m, 8H, 4 x H-6a,b), 3.55-3.53 (m, 4H, 4 x H-5), 3.47 (dd, J = 3.3 Hz, J = 9.9 Hz, 4H, 4 x H-3), 
3.43-3.37 (m, 36H, 4 x C-2, 16 x CH2 TEG), 3.30-3.27 (m, 8H, 4 x CH2 pentaerythritol) ppm; 13C NMR 
(100 MHz, D2O) δ = 125.7 (8C, CH triazole), 103.1 (4C, 4 x C-1), 76.2 (4C, 4 x C-5), 73.9 (4C, 4 x C-3), 
71.7 (4C, 4 x C-2), 70.7, 70.6, 70.5, 69.7 (24C, 24 x OCH2 TEG), 69.6 (4C, 4 x C-4), 69.3 (4C, 4 x CH2 
pentaerythritol), 62.7 (8C, 8 x CH2 propargyl), 62.0 (4C, 4 x C-6), 51.0 (8C, 8 x NCH2 TEG), 45.8 (1C, 
Cq pentaerythritol) ppm; MALDI-TOF (positive ion): m/z calcd for C85H140N24NaO40: 2159.96 [M + Na]+ 
Found: 2159.95. 
2.2.7. Compound 9  
Azide compound 8 (50 mg, 0.08 mmol) and alkyne 2 (139 mg, 0.36 mmol) were reacted in CH3CN 
according to general method A. The crude product was purified by flash column chromatography 
(97:3 CH2Cl2:MeOH) to give compound 9 (125 mg, 89%) as a colourless syrup. [α]24D—22.9 (c 0.17, 
CHCl3); Rf 0.11 (97:3 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3) δ = 7.84, 7.76, 7.51, 7.50 (4 x s, 6H, 6 
x CH triazole), 7.40 (s, 2H, arom), 5.39 (s, 3H, 3 x skeleton protons), 5.20–4.94 (m, 24H, 6 x CH2 
propargyl, 6 x CH2 ethylene glycol), 4.91-4.88 (m, 3H, 3 x skeleton protons), 4.76-4.71 (m, 3H, 3 x 
skeleton protons), 4.63–4.60 (m, 3H, 3 x H-1), 4.19-4.09 (m, 6H, 3 x H-6a,b), 3.98-3.97 (m, 3H, 3 x H-5), 
3.90 (s, 3H, COOCH3), 2.14, 2.04, 1.99, 1.97 (4 x s, 36H, 12 x CH3 acetyl) ppm; 13C NMR (100 MHz, 
CDCl3) δ = 170.5, 170.3, 170.1, 170.0, 169.6 (12C, 12 x CO acetyl), 166.2 (1C, COOCH3), 151.8 (2C, 2 x 
Cq arom), 143.7, 141.4 (6C, 6 x Cq triazole), 124.2 (2C, 2 x Cq arom), 124.1 (6C, 6 x CH triazole), 109.1 
(2C, arom), 100.4 (3C, 3 x C-1), 70.9, 70.8, 68.8, 67.1 (12C, 3 x skeleton carbons), 62.8, 62.7 (3C, 3 x C-
6), 61.3 (6C, 6 x CH2 propargyl), 52.5 (1C, COOCH3), 49.6, 49.5 (6C, 6 x NCH2 ethylene glycol), 20.8, 
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20.7, 20.6 (12C, 12 x CH3 acetyl) ppm; MALDI-TOF (positive ion): m/z calcd for C74H92N18NaO35: 
1815.59 [M + Na]+ Found: 1815.46. 
2.2.8. Compound 10  
Compound 9 (62 mg, 0.03 mmol) was deacetylated according to general method B. The crude 
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 10 (42 
mg, 94%) as a colourless syrup. [α]24D—8.0 (c 0.10, H2O); Rf 0.34 (7:3 CH3CN:H2O); 1H NMR (400 MHz, 
D2O) δ = 7.97, 7.90, 7.83 (3 x s, 6H, 6 x CH triazole), 7.32 (s, 2H, arom), 5.13–4.73 (m, 24H, 6 x CH2 
propargyl, 6 x CH2 ethylene glycol), 4.39 (d, J = 7.2 Hz, 3H, 3 x H-1), 3.91–3.90 (m, 6H, 3 x H-4, 
COOCH3), 3.80-3.75 (m, 6H, 3 x H-6a,b), 3.56-3.60 (m, 6H, 3 x H-5, 3 x H-3), 3.54–3.50 (m, 3H, 3 x H-2) 
ppm; 13C NMR (100 MHz, D2O) δ = 168.8 (1C, COOCH3), 152.1 (2C, 2 x Cq arom), 141.0 (6C, 6 x Cq 
triazole), 126.6 (2C, 2 x Cq arom), 125.5 (6C, 6 x CH triazole), 110.1 (2C, arom), 102.8 (3C, 3 x C-1), 76.2 
(3C, 3 x C-5), 73.7 (3C, 3 x C-3), 71.6 (3C, 3 x C-2), 69.5 (3C, 3 x C-4), 62.5 (6C, 6 x CH2 propargyl), 61.9 
(3C, 3 x C-6), 53.8 (1C, COOCH3), 50.9, 50.7 (6C, 6 x NCH2 ethylene glycol) ppm; MALDI-TOF 
(positive ion): m/z calcd for C50H68N18NaO23: 1311.46 [M + Na]+ Found: 1311.45. 
2.2.9. Compound 12  
Azide compound 11 (96 mg, 0.14 mmol) and alkyne 2 (315 mg, 0.82 mmol) were reacted in 
CH3CN according to general method A. The crude product was purified by flash column 
chromatography (95:5 CH2Cl2:MeOH) to give compound 12 (150 mg, 51%) as a colourless syrup. 
[α]24D—16.1 (c 0.23, CHCl3); Rf 0.27 (95:5 CH2Cl2: MeOH); 1H NMR (400 MHz, CDCl3) δ = 7.59, 7.52 (2 
x s, 8H, 8 x CH triazole), 5.41 (d, J = 2.1 Hz, 4H, 4 x H-4), 5.18 (dd, J = 8.1 Hz, J = 10.2 Hz, 4H, 4 x H-2), 
5.04 (dd, J = 3.2 Hz, J = 10.4 Hz, 4H, 4 x H-3), 4.95-4.73 (m, 24H, 12 x CH2), 4.65 (d, J = 7.9 Hz, 4H, 4 x 
H-1), 4.51 (s, 8H, 4 x CH2), 4.21-4.11 (m, 8H, 4 x H-6a,b), 4.01-3.97 (m, 4H, 4 x H-5), 3.37 (s, 8H, 4 x CH2 
pentaerythritol), 2.14, 2.05, 1.99, 1.98 (4 x s, 48H, 16 x CH3 acetyl) ppm; 13C NMR (100 MHz, CDCl3) δ 
= 170.4, 170.2, 170.0, 169.6 (16C, 16 x CO acetyl), 145.4, 144.2 (8C, 8 x Cq triazole), 124.0, 123.7 (8C, 8 x 
CH triazole), 100.3 (4C, 4 x C-1), 70.8, 70.7, 68.7, 67.1 (16C, 4 x skeleton carbons), 68.9 (4C, 4 x CH2 
pentaerythritol), 64.6 (4C, 4 x CH2 propargyl), 62.6 (4C, 4 x C-6), 61.2 (4C, 4 x CH2 propargyl), 49.5, 
49.3 (8C, 8 x NCH2 ethylene glycol), 45.1 (1C, Cq pentaerythritol), 20.8, 20.7, 20.6, 20.5 (16C, 16 x CH3 
acetyl) ppm;MALDI-TOF (positive ion): m/z calcd for C93H124N24NaO44: 2303.81 [M + Na]+ Found: 
2304.49. 
2.2.10. Compound 13  
Compound 12 (148 mg, 0.06 mmol) was deacetylated according to general method B. The crude 
product was purified by flash column chromatography (7:3 CH3CN:H2O) to give compound 13 (70 
mg, 66%) as a colourless syrup. [α]24D + 44.8 (c 0.31, H2O); Rf 0.20 (7:3 CH3CN:H2O); 1H NMR (400 
MHz, D2O) δ = 7.94 (s, 8H, 8 x CH triazole), 4.97 (s, 16H, 8 x NCH2 ethylene glycol), 4.93–4.78 (m, 16H, 
8 x CH2 propargyl), 4.44 (d, J = 7.6 Hz, 4H, 4 x H-1), 3.94 (d, J = 2.8 Hz, 4H, 4 x H-4), 3.83–3.74 (m, 8H, 
4 x H-6a,b), 3.71-3.68 (m, 4H, 4 x H-5), 3.65 (dd, J = 3.0 Hz, J = 9.8 Hz, 4H, 4 x H-3), 3.57–3.53 (m, 4H, 
4 x H-2), 3.34 (s, 8H, 4 x CH2 pentaerythritol) ppm; 13C NMR (100 MHz, D2O) δ = 125.4 (8C, 8 x CH 
triazole), 102.9 (4C, 4 x C-1), 76.2 (4C, 4 x C-5), 73.7 (4C, 4 x C-3), 71.6 (4C, 4 x C-2), 69.6 (4C, 4 x C-4), 
69.2 (4C, 4 x CH2 pentaerythritol), 62.5 (8C, 8 x CH2 propargyl), 61.9 (4C, 4 x C-6), 50.9 (8C, 8 x NCH2 
ethylene glycol), 45.5 (1C, Cq pentaerythritol) ppm; MALDI-TOF (positive ion): m/z calcd for 
C61H92N24NaO28: 1631.64 [M + Na]+ Found: 1631.59. 
2.3. Lectin PA-IL Production and Purification 
PA-IL in a recombinant form was produced and purified as previously described [8]. Briefly, 
transformed Escherichia coli BL21(DE3) cells bearing the plasmid for PA-IL (pET25b_pa1l) were 
cultured in the LB broth medium containing an appropriate antibiotic at 37 °C. When the culture 
reached an OD600 of ≈ 0.5, protein production was induced by isopropyl 1-thio-β-D-galactopyranoside 
(IPTG) added to a final concentration of 0.5 mM. Cells were incubated at 30 °C for 3 h, harvested by 
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centrifugation and resuspended in a suitable buffer. Cells were then disintegrated by sonication and 
the cytosolic fraction containing soluble lectin was separated by centrifugation. PA-IL was then 
purified by affinity chromatography on a Sepharose 4B (GE Healthcare, Chicago, IL, USA) column, 
dialyzed and further processed according to the previously published procedures [8]. Freeze-dried 
PA-IL was stored at −20 °C. 
2.4. Hemagglutination Inhibition Assay (HIA) 
PA-IL was dissolved in the buffer with calcium ions suitable for the activity of the lectin (20 mM 
Tris/HCl, 150 mM NaCl, 5 mM CaCl2, pH = 7.5) to the concentration 0.25 mg mL−1. Lectin was mixed 
with carbohydrate inhibitors serially diluted in the buffer in a 5 µL:5 µL ratio. Therefore, the final 
(working) concentration of the lectin was 0.125 mg mL−1. A total of 10 µL of 20% papain-treated, azid-
stabilized red blood cells B+ in the buffer was then added, and the mixture was thoroughly mixed 
and incubated for 5 min at room temperature. After incubation, the mixture was again mixed, 
transferred to a microscope slide, and examined. The examination was conducted using the 
Levenhuk D2L NG Digital Microscope (Levenhuk, Tampa, FL, USA). Images were obtained with a 
Levenhuk D2L digital camera (Levenhuk, Tampa, FL, USA) using the software ToupView for 
Windows (Version 3.7, Levenhuk, Tampa, FL, USA). The positive (experiment without inhibitor) and 
negative control (experiment without lectin) were prepared and processed in the same way using the 
appropriate volume of dissolving buffer instead of the omitted components. The minimal inhibitory 
concentration (MIC) of the inhibitor able to inhibit hemagglutination was determined and compared 
with the standard (D-galactose) and the potency of the inhibitor was calculated (MIC of the 
standard/MIC of the inhibitor). 
2.5. Surface Plasmon Resonance (SPR) 
Surface plasmon resonance (SPR) experiments were performed on a BIAcore T200 instrument 
(GE Healthcare, Chicago, IL, USA) at 25 °C, using HBST running buffer (10 mM HEPES, 150 mM 
NaCl, 0.5 mM CaCl2, 0.05% Tween 20, pH = 7). A CM5 sensor chip (GE Healthcare, Chicago, IL, USA) 
covered with a carboxymethylated dextran matrix was used for ligand immobilization. The sensor 
chip surface was activated with N-ethyl-N-(3-dimethylaminopropyl)carbodiimide/N-
hydroxysuccinimide solution and then coated with streptavidin (Sigma-Aldrich, St. Louis, MO, USA) 
in 10 mM acetate pH = 5.0 according to the manufacturer’s standard protocol to a final response of 
7000 RU. Unreacted groups were blocked with 1 M ethanolamine-HCl, pH = 8.5. 0.5 mM biotinylated 
carbohydrate (1:1 mixture of biotin-α-D-galactoside and biotin-β-D-galactoside for measuring 
channel and α-L-fucoside for blank channel, all Lectinity, Moskow, Russia) was injected into a 
particular channel at a flow rate of 5 µL min−1. 
In the experimental setup, SPR inhibition measurements were carried out simultaneously on 
both measuring and blank channels at a flow rate of 5 µL min−1. Protein PA-IL at a concentration of 
45 µM was mixed with various concentrations of inhibitors (0.1–125 µM for studied compounds or 
5–5000 µM for D-galactose) and injected onto the sensor chip. The response of the blank channel was 
subtracted from the response of lectin bound to the galactose-modified surface at equilibrium and 
plotted against the concentration of inhibitor in order to determine IC50 (concentration of inhibitor 
resulting in 50% inhibition of binding). As IC50 is not a constant and depends on the experimental set-
up, a parameter called potency was used for characterization. The potency of a tested inhibitor is the 
ratio of IC50 of a chosen standard inhibitor (in this case, D-galactose) and the inhibitor in question. 
Pure lectin PA-IL was used as a control (0% inhibition). 
2.6. Isothermal Titration Microcalorimetry (ITC) 
All the experiments were performed on MicroCal iTC200 (Malvern Instruments, Malvern, UK) 
at 25 °C. The freeze-dried lectin PA-IL was dissolved in 0.1 M Tris/HCl, 500 µM CaCl2, pH = 7.5, and 
equilibrated at room temperature for 1 h before ITC measurements. Multivalent galactosylated 
compounds 4, 7, 10 and 13 were diluted in the same buffer and used in 0.25–0.5 mM concentrations. 
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Aliquots of 2 µL of the compounds were added automatically to the 0.078 mM or 0.088 mM PA-IL in 
the calorimeter cell. Blank experiments (injections of compounds to the buffer) were performed and 
heat responses were subtracted. Integrated heat effects were analyzed by global fitting of data 
obtained from three independent titrations for each tested compound by non-linear regression using 
a single site-binding model (Microcal Origin 7, Malvern Instruments, Malvern, UK). Fitted data 
yielded the association constant (Ka) and the enthalpy of binding (ΔH). Other thermodynamic 
parameters, i.e., changes in free energy (ΔG) and entropy (ΔS), were calculated from the following 
equation: ΔG = ΔH − TΔS = −RT ln Ka, where T is the absolute temperature and R = 8.314 J mol−1 K−1. 
The monosaccharide D-galactose was used as a control; 4 mM D-galactose was added to the 0.147 mM 
PA-IL in the calorimeter cell. Two titration experiments were performed and the heat responses were 
processed and evaluated as mentioned above.  
2.7. Analytical Ultracentrifugation (AUC) 
Analytical ultracentrifugation experiments were performed using ProteomeLab XL-I analytical 
ultracentrifuge (Beckman Coulter, Indianapolis, IN, USA) equipped with an An-60 Ti rotor. 
Sedimentation velocity experiments were conducted in titanium double-sector centerpiece cells 
(Nanolytics Instruments, Potsdam, Germany) loaded with 390 µL of both protein sample and 
reference solution (PBS buffer, pH = 7.5). PA-IL without the added ligand and PA-IL samples pre-
incubated with different concentrations of galactosylated dendrimers 4, 7, 10 and 13 and D-galactose 
(protein:ligand ratios of 1:0.1, 1:1 and 1:10) were analyzed by the sedimentation velocity experiment. 
All the measurements were performed in PBS buffer with 22 µM PA-IL. Data were collected using 
absorbance optics at 25 °C at a rotor speed of 48,000 rpm. Scans were collected at 280 nm (or 
alternatively at 294 nm to decrease the absorbance signal of the samples containing excess of the UV-
absorbing ligands 4 and 10) at 5-min intervals and 0.003 cm spatial resolution in continuous scan 
mode. The partial specific volume of the protein and the solvent density and viscosity were calculated 
from the amino acid sequence and buffer composition, respectively, using the software Sednterp 
(http://bitcwiki.sr.unh.edu). The data were analyzed with the continuous c(s) distribution model 
implemented in the program Sedfit 15.01b [27]. For the regularization procedure, a confidence level 
of 0.95 was used. The plots of c(s) distributions were created in GUSSI 1.3.1 [28]. 
2.8. Pseudomonas Aeruginosa Cross-Linking Assay 
Pseudomonas aeruginosa CCM 3955 (ATCC 27853) cells were inoculated from stock cells stored at 
−80 °C into a standard LB medium and were grown at 37 °C overnight under orbital shaking. The 
bacterial culture was kept in the fridge until further use. Prior to the experiment, bacterial cells were 
centrifuged at 4,300× g (Eppendorf centrifuge MiniSpin, Eppendorf, Germany) for 2 min and 
subsequently washed three times with PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4). Bacterial cells were then diluted in PBS to an optical density OD600 = 1.5, which was 
checked using a spectrophotometer (WPA CO8000 Biovawe Cell Density Metr, Biochrom Ltd., 
Cambridge, UK). D-galactopyranoside-presenting inhibitors were diluted in ultrapure water to the 
concentration of 100 mM. Bacterial cells were mixed in a 9:1 ratio with the 10x concentrated selected 
compounds and gently mixed. The mixture was incubated at room temperature for 10 min and 
thoroughly mixed again. An amount of 5 µL of the mixture was transferred onto a microscope slide 
and observed under 100x magnification using an optical microscope (Olympus IX81F-3/IX81S1F-3, 
Olympus, Tokyo, Japan). As a negative control, bacterial culture mixed with ultrapure water in 9:1 
ratio was used. The images were obtained using a phase contrast method and the background of the 
images was subtracted in GIMP. 
2.9. Pseudomonas Aeruginosa Adherence Assay 
2.9.1. Cell Labelling 
Epithelial CuFi-1 cells (an immortalized epithelial cell line derived from cystic fibrosis human 
lungs, ATCC, Kielpin, Poland) were labelled with PKH67 (Fluorescent Cell Linker Kit, Sigma-
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Aldrich, St. Louis, MO, USA), a green fluorescent membrane marker, as follows. An aliquot of cell 
suspension containing 7 × 106 cells was washed with PBS buffer and centrifuged (100× g for 5 min). 
The cell pellet was resuspended in 250 µL of Diluent C (Fluorescent Cell Linker Kit, Sigma-Aldrich, 
St. Louis, MO, USA). Immediately, an equal volume of 8 µM PKH67 in Diluent C (2 µL of PKH67 in 
248 µL of Diluent C) was added to the cell suspension. After 5 min incubation at room temperature 
with periodic mixing, the staining reaction was stopped by adding an equal volume of 1% Fetal 
Bovine Serum (FBS, GibcoTM Invitrogen, Paisley, UK) in PBS. After 1 min incubation with FBS, the 
suspension was centrifuged (100× g for 10 min). Finally, the cells were washed three times with 
Bronchial Epithelial Cell Growth Basal Medium (Lonza, Basel, Switzerland), followed by 
centrifugation (100× g for 5 min). 
Pseudomonas aeruginosa strain 1763 (University Hospital Motol, Prague, Czech Republic) was 
stained with PKH26 (Fluorescent Cell Linker Kit, Sigma-Aldrich, St. Louis, MO, USA), a red 
fluorescent membrane marker. Bacteria were grown in a suspension culture in PS medium 
(peptone/casein digest) in an Erlenmeyer flask for 14 h. The culture was washed with PBS buffer and 
centrifuged (13,400× g for 5 min). The pellet containing 1.5 × 109 bacteria was resuspended in 125 µL 
of Diluent C (Fluorescent Cell Linker Kit, Sigma-Aldrich, St. Louis, MO, USA) and an equal volume 
of 16 µM PKH26 in Diluent C (2 µL of PKH26 in 123 µL of Diluent C) was added to the bacterial 
suspension. The bacteria/dye suspension was incubated for 30 min at room temperature with 
periodic mixing. The staining was quenched by adding an equal volume of 1% BSA (Bovine Serum 
Albumin, Merck, Kenilworth, NJ, USA) in PBS. The suspension was incubated with BSA for 1 min to 
allow the binding of excess dye and then centrifuged (15,700× g for 10 min). Bacteria were washed 
two times with PBS, followed by centrifugation (13,400× g for 7.5 and 5 min). 
2.9.2. Inhibition of Pseudomonas Aeruginosa Adhesion to Epithelial Cells 
Epithelial cells CuFi-1 stained with PKH67 were seeded at 8.4 × 104 cells/well onto 96-well plates 
(CellBIND® 96-well Flat Clear Bottom Black Polystyrene Microplates, Corning Incorporated, Corning, 
NY, USA) and incubated for 42–45 h at 37 °C, 5% CO2 to form a confluent monolayer and regenerate. 
Prior to the assay, wells were washed with PBS. Compounds 4, 7, 10 and 13 were serially diluted with 
PBS to the desired concentrations. PKH26-stained bacteria P. aeruginosa were added to the diluted 
inhibitor solutions. Bacterial suspensions were immediately added to the wells (50 µL/well). The 
input ratio was about 100 bacteria per epithelial cell (8.4 × 106 bacteria/well). A suspension without 
any inhibitor was used as a control. After 2 h incubation at room temperature, the wells were 
extensively washed three times with PBS to remove non-adhered bacteria. The fluorescence of 
adhered P. aeruginosa cells (Ex 522 nm, Em 569 nm for PKH26) on epithelial cells (Ex 470 nm, Em 505 
for PKH67) was quantified using the spectrofluorometer Tecan Infinite M200 Pro (Tecan Group Ltd., 
Männedorf, Switzerland). Results were expressed as a relative fluorescence ratio of P. 
aeruginosa/CuFi-1. Three independent incubations were performed.  
The effect of compounds 10 and 13 in combination with previously published tetravalent α-L-
fucose-presenting glycocluster (compound 14, see Figure 1) [29] was also determined. Compounds 
10 and 13, respectively, were serially diluted and mixed with compound 14 in a constant 
concentration of 0.25 mM. PKH26-stained bacteria P. aeruginosa were added to the inhibitors solutions 
and experiments were performed and evaluated as mentioned above. In addition to control 
(suspension without any inhibitor), the bacterial suspension with only 0.25 mM compound 14 was 
also processed and evaluated. Data were analyzed in GraphPad Prism 7 (GraphPad Software, Inc., 
San Diego, CA, USA).  
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Figure 1. The tetravalent, α-L-fucoside-containing inhibitor with tetraethylene glycol bridges 
(compound 14) [29]. 
3. Results 
3.1. Synthesis of Multivalent Galactosides 
 
Scheme 1. Synthesis of multivalent galactosides. 
Similarly to our recent studies [25,30,31], metyl gallate equipped with azide-containing 
tetraethylene glycol 1 and ethylene glycol chains 8 and pentaerythritol cores 5 and 11 [25] were chosen 
as multivalent scaffolds (Scheme 1.). We efficiently prepared peracetylated propargyl β-D-
galactopyranoside 2 by known method [32]. The galactoclusters were built from the above structural 
elements by applying 1,3-dipolar azide-alkyne cycloaddition click reactions. First, the trivalent cores 
1 and 8 were coupled with propargyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2 via the Cu(I)-
catalyzed azide-alkyne cycloaddition click reaction (CuAAC) to get protected trivalent galactosides 
Biomolecules 2019, 9, 686 10 of 22 
3 and 9, in good yields. Similarly, tetravalent scaffolds 5 and 11 were coupled by CuAAC reaction 
with galactoside 2 to produce the protected galactoclusters 6 and 12, respectively. The final products 
were obtained by Zemplén-deacetylation of 3, 6, 9 and 12, to result in compounds 4, 7, 10 and 13, 
respectively, showing differences in the valency, flexibility and spatial arrangement of galactosides. 
Compounds were tested as potential ligands of tetrameric, galactose-specific lectin PA-IL. 
3.2. Inhibition of PA-IL with Multivalent Galactosylated Compounds 
The preliminary investigations of the interactions of the multivalent galactosylated compounds 
with PA-IL were performed using hemagglutination inhibition assay with microscope detection. The 
minimal inhibitory concentrations (MICs) of compounds able to completely inhibit hemagglutination 
caused by lectin PA-IL were determined and the potencies of the inhibitors were calculated by 
comparison with the standard (D-galactose). All compounds were able to inhibit hemagglutination 
significantly better than simple D-galactose (see Table 1 and Figure 2) with compound 7 being the 
best inhibitor—256 times better than D-galactose. The least efficient inhibitor was compound 10 (with 
potency value of 64), whereas compounds 4 and 13 were in between (128). Taking into account the 
simple effect of the increased concentration of galactose units in the multivalent compound 
(parameter β, potency/valency), compound 7 (the tetravalent compound with longer linkers, β = 64) 
is still the best inhibitor and compound 10 (trivalent with shorter ethylene-linker, β = 21.3) the least 
efficient. Considering compounds 4 and 13, differences in inhibitory efficiency were observed. 
Compound 4 (trivalent, tetraethylene glycol-linker, β = 42.7) was better than compound 13 
(tetravalent, ethylene-linker, β = 32). Generally, a more efficient inhibitory activity was associated 
with tetravalent compounds and longer linkers. 
Table 1. The MIC (minimal inhibitory concentration) values and potencies of tested inhibitors 
obtained for the inhibition of hemagglutination caused by lectin PA-IL. 
Inhibitor MIC  Potency 2 Valency β 3 
D-galactose 1 6.25 mM 1 1 1 
Compound 4 48.83 µM 128 3 42.7 
Compound 7 24.41 µM  256 4 64 
Compound 10 97.66 µM 64 3 21.3 
Compound 13 48.83 µM  128 4 32 
1 Standard, 2 MIC of standard/MIC of inhibitor, 3 Potency/Valency. 
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Figure 2. Influence of D-galactose, compounds 4, 7, 10, and 13 on hemagglutination caused by lectin 
PA-IL. Positive control: experiment without inhibitor. Negative control: experiment without lectin 
PA-IL. 
The surface plasmon resonance (SPR) technique was employed to further analyse the 
competitive inhibition of PA-IL binding to a multivalent chip surface. Sensor chip presenting D-
galactopyranoside residues was treated by a constant concentration of PA-IL, and the concentrations 
of the tested inhibitors were gradually decreased to determine IC50. All the tested compounds clearly 
demonstrated a higher inhibition potency when compared to D-galactose (see Table 2). The most 
potent inhibitor appeared to be compound 13, with a more than 40 times higher inhibition potency 
than D-galactose (more than 10 times when calculating parameter β considering the effect per 
monomer unit) followed by compounds 4, 10 and 7, that displayed almost identical inhibitory effects 
(see Figure 3).  
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Table 2. The IC50 (concentration of inhibitor resulting in 50% inhibition of binding) values and 
potencies of the tested inhibitors obtained by SPR for lectin PA-IL. 
Inhibitor IC50  Potency 2 Valency β 3 
D-galactose 1 187.1 µM 1 1 1 
Compound 4 6.8 µM 27.5 3 9.2 
Compound 7 7.3 µM 25.6 4 6.4 
Compound 10 7.4 µM 25.3 3 8.4 
Compound 13 4.3 µM 43.5 4 10.9 
1 Standard, 2 IC50 of standard/IC50 of inhibitor, 3 Potency/Valency. 
 
Figure 3. Inhibitory effects of tested compounds on lectin PA-IL binding to immobilized D-
galactosides obtained by SPR. Individual type of line corresponds to monovalent (dotted), trivalent 
(solid) and tetravalent (dashed) ligands. D-galactose was used as a control and standard. 
3.3. Thermodynamics of the Interactions 
The interactions of PA-IL with D-galactopyranoside-presenting glycoclusters were directly 
characterized by isothermal titration calorimetry. All the compounds were able to bind to PA-IL with 
an affinity three orders of magnitude higher than simple D-galactose (see Table 3). Interactions were 
exothermic- and enthalpy-driven, with significantly unfavourable entropy. Interactions with 
tetravalent compounds displayed higher unfavourable entropy values than those with trivalent 
compounds, probably corresponding to the larger loss of flexibility during binding. However, the 
entropy loss was connected with increased favourable enthalpy values in an example of enthalpy-
entropy compensation [33]. The best binding partner for lectin PA-IL, according to the obtained 
affinity constants, was compound 13, followed by compound 7, i.e., the tetravalent variants. The 
stoichiometry (n value) of interactions was lower than 1, suggesting that one molecule of inhibitor is 
recognized by several binding sites of lectin PA-IL. No aggregation was observed during or after the 
calorimetry experiments, implying that the binding is either intramolecular (within the same PA-IL 
tetramer) or the particles resulting from intermolecular binding are too small to form visually 
observable aggregates. 
Table 3. Thermodynamic parameters of the interactions between lectin PA-IL and the tested inhibitors. 
Inhibitor Valency  n Ka [104 M−1] 
D-galactose  1 0.78 ± 0.05 0.68 ± 0.038 
Compound 4 3 0.51 ± 0.01 128 ± 15.1  
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Compound 7 4 0.32 ± 0.01 281 ± 23.5  
Compound 10 3 0.53 ± 0.01 122 ± 12.8  
Compound 13 4 0.21 ± 0.01 470 ± 54.5 
Inhibitor ΔH [kJ/mol] −TΔS [kJ/mol] ΔG [kJ/mol] 
D-galactose  −37.8 ± 2.92 15.9 ± 2.12 −21.9 ± 1.23 
Compound 4 −80.7 ± 1.01 45.9 ± 5.99 −34.8 ± 4.11 
Compound 7 −110.0 ± 0.82 72.7 ± 6.65 −36.8 ± 3.09 
Compound 10 −68.2 ± 0.75 33.4 ± 3.87 −34.7 ± 3.64 
Compound 13 −134.0 ± 1.45 95.7 ± 12.15 −38.1 ± 4.42 
3.4. Cross-linking of Lectin PA-IL with Multivalent Galactosylated Inhibitors 
The sedimentation velocity experiment was used to investigate the cross-linking properties of 
the galactosylated dendrimers (compounds 4, 7, 10 and 13) on the lectin PA-IL. In the absence of 
dendrimers, PA-IL was mostly present as a tetramer with the sedimentation coefficient of 4.2 S 
(estimated molar mass of 48.4 kDa), about 5% of PA-IL had an s-value of 6.4 S and corresponded most 
likely to an octameric species. The addition of dendrimers 7, 10 and 13 (but not 4) induced the 
formation of the 6.4 S particle (see Figure 4). At a 1:0.1 protein to ligand ratio, the highest level of 
cross-linking was observed for compound 7 (~30%), followed by compounds 10 and 13 (~15%). In the 
molar excess of the ligand, the percentage of 6.4 S species decreased and was comparable to the 
sample without the ligand added. The ligands (if absorbing in UV) had a sedimentation coefficient 
between 0.3 and 0.5 S. Since the formation of larger oligomers or precipitation were not detected by 
analytical ultracentrifugation, the data suggests that dendrimers 7, 10 and 13 cross-link PA-IL in a 
well defined way (formation of octamers). In the control experiment, D-galactose had a negligible 
effect on the percentage of the 6.4 S particle (see Figure S1). According to the results, trivalent 
compound 4 did not form intermolecular cross-links in the used set-up, probably due to the 
combination of the topology of its branches and the length of its linkers. Compared with the trivalent 
compound 10, which forms intermolecular cross-links, the longer linkers of compound 4 are probably 
more suitable for intramolecular binding to several binding sites of PA-IL. In the molar excess of all 
the compounds, the binding sites of PA-IL seemingly bind separate molecules of dendrimers, which 
prevents cross-linking. 
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Figure 4. Continuous c(s) distributions of PA-IL samples obtained in the absence and presence of 
multivalent galactosylated dendrimers. The distributions were obtained at different protein to ligand 
ratios (see the legend). The c(s) curves obtained at 294 nm (instead of 280 nm) are marked with a star. 
(a) Results for compound 4; (b) Results for compound 7; (c) Results for compound 10; (d) Results for 
compound 13. 
3.5. Cross-linking of Pseudomonas Aeruginosa Cells with Multivalent Galactosylated Inhibitors 
The abilities of D-galactopyranoside-presenting inhibitors to cross-link whole Pseudomonas 
aeruginosa cells via interactions with lectin PA-IL on the surface were investigated by cell cross-
linking assay with microscope detection. The cell aggregates clearly distinguishable from the 
negative control were only observed in low quantities and mainly in highly used concentrations of 
the tested compounds (2.5–5 mM, see Figure 5). The cell cross-linking activity of the tested 
compounds was either generally weak or the resulting cell aggregates were too small to be detected 
by the used methodology in the current set-up. Considering compound 13, no aggregates were 
observed, even in 5 mM concentration. On the other hand, compound 7 displayed the highest cross-
linking activity and aggregates distinguishable from the negative control were observed even in a 
concentration of 1.25 mM (see Figure S2). 
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Figure 5. Cross-linking of Pseudomonas aeruginosa cells with D-galactopyranoside-presenting 
inhibitors. The P. aeruginosa cells with no added inhibitors were used as a control. Magnification 100x, 
phase contrast, background subtraction in GIMP, triplicates. The results for the highest concentrations 
used are presented. For the other concentrations used, see Figures S2 and S3 in the Supplementary 
data. The representative aggregates are highlighted by the black arrows. (a) Results for compounds 4 
and 10; (b) Results for compounds 7 and 13. 
3.6. Inhibition of Pseudomonas Aeruginosa Adhesion to Epithelial Bronchial Cells 
Ex vivo bacterial adherence assay was used for the evaluation of the ability of tested compounds 
to inhibit the adhesion of P. aeruginosa (ST 1763, isolated from a CF patient) to epithelial bronchial 
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cells (CuFi-1, derived from a CF patient). Bacteria labeled with PKH26 were incubated with PKH67-
labeled CuFi-1 in the presence of compounds 4, 7, 10 and 13 or PBS as untreated control (see Figure 
6). Compounds 4 and 7 displayed no inhibitory effect on bacterial adhesion compared to the control. 
On the contrary, compounds 10 and 13 had a significant protecting effect in concentrations ≥1 mM. 
In the highest concentration (2 mM), compounds 10 and 13 were able to reduce bacterial adhesion to 
approximately 32% and 42%, respectively, compared to the untreated control. However, the addition 
of compounds 10 and 13 in some lower concentrations (≤125 µM) resulted in a statistically 
significantly increased fluorescent signal (see Figure 6c,d). Furthermore, the combined effect of anti-
PA-IL inhibitors (compounds 10 and 13) and the previously published PA-IIL inhibitor (compound 
14) was tested (see Figure 7). PA-IIL (LecB) is another lectin from Pseudomonas aeruginosa involved in 
pathogenicity [8]. According to the previous study, compound 14 was used in its most effective 
concentration (250 µM) [29] and combined with the concentration gradient of compound 10 or 13. 
The mixtures of compounds 10 or 13 in the highest concentration (2 mM) with compound 14 (250 
µM) reduced the P. aeruginosa adhesion to approximately 22% and 23%, respectively. Considering 
these combined experiments, no response exceeding the untreated control was observed for any used 
concentration of compounds 10 and 13.  
 
Figure 6. Adherence of P. aeruginosa to human bronchial epithelial cells (CuFi-1) in the presence of 
the tested compounds. Monolayers of PKH67-labeled CuFi-1 cells were incubated for 2 h with 
suspensions containing PKH26-labeled P. aeruginosa and tested compounds (grey bars) or PBS as a 
control (black bars). After discarding of non-adhered bacteria, the relative fluorescence of adhered P. 
aeruginosa and CuFi-1 was quantified using Tecan Infinite M200 Pro. Results are expressed as a 
relative fluorescence ratio of P. aeruginosa/CuFi-1 plotted as a function of compounds concentrations. 
Plotted data are means ± SD of three independent incubations. * indicates significant difference (p < 
0.05; Dunnett test). (a) Results for compound 4; (b) Results for compound 7; (c) Results for compound 
10; (d) Results for compound 13. 
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Figure 7. Adherence of P. aeruginosa on CuFi-1cells in the presence of compounds combination. 
Monolayers of PKH67-labeled CuFi-1 cells were incubated for 2 h with suspensions containing 
PKH26-labeled P. aeruginosa and 250 µM compound 14 combined with compound 10 or 13 (dark grey 
bars) or only 250 µM compound 14 (light grey bar). Suspension with PKH26-labeled P. aeruginosa in 
PBS was used as an untreated control (black bar). After discarding non-adhered bacteria, the relative 
fluorescence of adhered P. aeruginosa and CuFi-1 was quantified using Tecan Infinite M200 Pro. 
Results are expressed as a relative fluorescence ratio of P. aeruginosa/CuFi-1 plotted as a function of 
anti-PA-IL compounds concentration. Plotted data are means ± SD of three independent incubations. 
* indicates significant difference from untreated control (p < 0.05; Dunnett test). # indicates significant 
difference from experiment using only 250 µM compound 14 (p < 0.05; Dunnett test). (a) Results for 
compound 10; (b) Results for compound 13. 
4. Discussion 
An expeditious click-chemistry approach was applied to synthesize tri- and tetravalent 
glycodendrimers of different flexibilities bearing the β-D-galactoside units with different spatial 
arrangements. The ability of the synthetized β-D-galactopyranoside-containing tri- and tetravalent 
glycoclusters to inhibit the lectin PA-IL (LecA) from Pseudomonas aeruginosa was determined by 
hemagglutination inhibition assay (HIA) with microscope detection and by SPR inhibition assay 
using immobilized D-galactopyranoside. Hemagglutination inhibition assay is a quick and robust 
method commonly used for characterization of lectin-carbohydrate interactions [34]. The 
carbohydrate-covered surface of red blood cells enables lectins to employ their multivalency and 
potential inhibitors could be suitably tested for their ability to compete with this native surface. On 
the other hand, hemagglutination assay relies fully on visual detection and thorough comparisons 
with positives and negatives controls. SPR inhibition assay in flow-through arrangement with 
carbohydrates immobilized on the static sensor chip could theoretically better mimic the real 
environment of lectin’s action—binding to lung tissues. However, SPR is sensitive to aggregation and 
potential artifacts caused by cross-linking of lectins [30]. By combination of these two diverse 
methods, their weaknesses could be compensated and the inhibitory activity of tested compounds 
verified. According to the hemagglutination assay, tetravalent compound 7 was the best inhibitor 
(potency 256, β = 64). However, the trivalent compound 4 (potency 128, β = 42.7) was the second best 
compound, suggesting a preference for compounds with longer and more flexible tetraethylene 
glycol-linker over shorter ethylene-linker, regardless of their valency. Considering SPR assay, 
compound 13 was determined to be the best inhibitor. In contrast to hemagglutination assay, there 
was no clear correlation observed between the compounds’ valency or structure and their inhibitory 
effect. This demonstrates not only the importance of structural arrangement of the studied 
compounds but also of the nature of the tested surface. As SPR and HIA have completely different 
set-ups and detection principles, the acquisition of different data was not surprising. The fact that 
diverse techniques for determination of inhibitory potency provide different and sometimes even 
contradictory results is well known [11,35] and hinders the reliable in vitro evaluation of inhibitors. 
Nevertheless, both methods confirmed that all the tested compounds could inhibit PA-IL 
significantly better than simple D-galactose. 
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The interactions of β-D-galactopyranoside-containing compounds and PA-IL were also 
characterized by isothermal titration microcalorimetry to obtain true binding affinities and 
thermodynamic parameters. Interactions were enthalpy-driven with strong unfavorable entropy. As 
carbohydrates are very flexible molecules, a strong entropy barrier is usually observed during 
binding, i.e., fixation of carbohydrates into the binding sites [36]. Binding affinities were three orders 
of magnitude higher than for D-galactose. The affinities obtained by ITC are not equal to inhibitory 
activities but could correlate with them. The best ligand for the lectin PA-IL in the ITC set-up (in 
solution method) was compound 13, followed by compound 7, i.e., the tetravalent ligands. Although 
the entropy loss was significantly higher during interactions with tetravalent compounds than with 
trivalent, the enthalpy compensation resulted in higher affinities to tetravalent variants. The 
combination of inhibition assays and direct affinity measurement confirms that the tested 
compounds are suitable ligands/inhibitors of lectin PA-IL but the variation of the results (see Figure 
8) obtained by different methods thwarted the straightforward selection of compounds with the 
highest potential to affect Pseudomonas aeruginosa in vivo. 
 
Figure 8. Comparison of effectiveness of tested compounds obtained by hemagglutination inhibition 
assay (HIA), SPR inhibition assay (SPR) and isothermal titration microcalorimetry (ITC). Values for 
parameters β (HIA and SPR) and Ka (ITC) were relativized to the best inhibitor/ligand (100%) obtained 
by each method and compared. 
The PA-IL-cross-linking ability of carbohydrate-based inhibitors was associated with their 
potential to inhibit Pseudomonas aeruginosa biofilm formation [23]. Moreover, to determine the 
possible correlation between cross-linking and anti-adhesion properties, analytical 
ultracentrifugation with lectin PA-IL and cross-linking assay with whole P. aeruginosa cells were 
employed. Considering AUC, compounds 7, 10 and 13 cross-linked PA-IL in well defined manner, 
forming octamers. The formation of octamers decreased in the molar excess of tested compounds, 
suggesting saturation of binding sites of PA-IL. Compound 7 was the best cross-linker; on the other 
hand, no cross-linking activity was observed for compound 4. The cross-linking assay with whole 
cells was further used to better mimic the in vivo condition. Formation of aggregates was observed 
for compounds 7, 10 and, in contrast to AUC, also for compound 4. On the other hand, no clearly 
distinguishable aggregates were detected when using compound 13. Generally, the number of 
aggregates was low, suggesting a low cross-linking activity in the used set-up or the formation of 
aggregates too small to be reliably detected by the utilized methodology.  
The contradictory results from inhibition/affinity assays and cross-linking assays demonstrates 
the problems with the in vitro evaluation of potential inhibitors. Since the in vivo testing (especially 
for potential human drugs) is beyond the possibility of basic research, the ex vivo bacterial adherence 
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assay was chosen as the closest possible to the real system. This assay was used to monitor the effect 
of the tested compounds on bacteria–cell interaction, utilizing the epithelial cells and P. aeruginosa 
strain derived from a cystic fibrosis (CF) patient and direct detection of adhered bacteria by 
fluorescence. Although compounds 4 and 7 performed well in in vitro tests, they have essentially no 
visible protective effect in the adhesion assay. On the other hand, compounds 10 and 13 displayed 
significant anti-adhesion effect in concentrations ≥1 mM and could be suitable for prophylaxis against 
the bacterial colonization of bronchial cells. However, the efficient concentrations were rather high, 
which could be difficult to achieve in vivo and could increase the possibility of negative side effects. 
Furthermore, the increase of fluorescence signal (i.e., the number of adhered bacterial cells) was 
observed in lower concentrations (≤125 µM) of compounds. This could have been caused by the cross-
linking of PA-IL on the surface of the bacterial cells and corresponds to the results from AUC assay. 
Alternatively, some galactose-binding protein on the surface of epithelial cells could additionally 
interact with β-D-galactopyranoside-containing compounds, linking bacteria and epithelial cells 
together. The insufficient maintenance of effective concentration in the lungs of CF patients could 
theoretically lead to an increased adhesion of P. aeruginosa to the tissues. Combined with the fact that 
compound 7 (the best cross-linker) failed in the adherence assay, the cross-linking ability cannot be 
associated with anti-adhesion properties. 
In addition to PA-IL, Pseudomonas aeruginosa also produces a fucose-specific lectin PA-IIL (LecB), 
which is involved in the adhesion and in the biofilm formation [37] and was shown to block ciliary 
beating of epithelial cells [8]. As PA-IIL has a completely different carbohydrate specificity than PA-
IL, the β-D-galactopyranoside-containing compounds cannot inhibit this lectin and combination of 
specific inhibitors is necessary for maximal inhibition of adhesion. Therefore, the combined effect of 
compounds 10 or 13, respectively, and previously prepared tetravalent α-L-fucose-presenting 
glycocluster 14 [29] was evaluated. The most effective combinations of inhibitors (2 mM compound 
10 or 13 plus 250 µM compound 14) were able to reduce bacterial adhesion to approximately 22% 
and 23%, respectively. The increase of fluorescent signal in lower concentrations of compounds 10 
and 13 (compared to the experiment using only 250 µM compound 14), was observed in these 
combined experiments, too. However, it did not exceed the value of untreated negative control. 
Therefore, we suggest the use of a combination of galactose/fucose-containing inhibitors for 
prophylaxis purposes to achieve maximal anti-adhesion activity and the elimination of possible 
negative effects caused by using only galactose-based inhibitors. Considering CF patients, the 
problem of highly effective concentrations of tested compounds could be overcome by the fact that it 
is feasible to reach high doses of medication applied directly to lungs via inhalation [38,39].  
5. Conclusions 
β-D-galactopyranoside-containing tri- and tetravalent glycoclusters, synthesized by click-
chemistry, were tested by a variety of methods to determine their inhibitory effect against the lectin 
PA-IL from Pseudomonas aeruginosa. All the compounds were found to be suitable inhibitors/ligands 
of the lectin in vitro, with a significantly better inhibitory effect/affinity than simple D-galactose. 
Compounds 10 and 13 were also able to decrease adhesion of P. aeruginosa cells to bronchial human 
cells in the ex vivo adhesion assay. In contrast to inhibition of biofilm formation [23], the cross-linking 
ability of multivalent inhibitors could not be directly associated with the anti-adhesion potential. The 
best results in adhesion assay were obtained for compounds 10 and 13 in combination with 
previously investigated tetravalent α-L-fucose-containing inhibitor of lectin PA-IIL, another 
virulence factor of P. aeruginosa. Therefore, future research will be focused on the simultaneous 
inhibition of both lectins, possibly by using mixed fucose/galactose-based inhibitors. In conclusion, 
tri- and a tetravalent compounds 10 and 13 are promising candidates for testing using a mouse cystic 
fibrosis model [40] with potential future utilization as prophylactic agents against bacterial 
colonization of lungs.  
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Continuous 
c(s) distributions of PA-IL samples obtained in the absence and presence of D-galactose. Figure S2: Cross-linking 
of Pseudomonas aeruginosa cells with D-galactopyranoside-presenting inhibitors. Results for compounds 7 and 13. 
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Figure S3: Cross-linking of Pseudomonas aeruginosa cells with D-galactopyranoside-presenting inhibitors. Results 
for compounds 4 and 10. Figure S4: 1H, 13C NMR, COSY and HSQC spectra of compound 4. Figure S5: 1H, 13C 
NMR, COSY and HSQC spectra of compound 7. Figure S6: 1H, 13C NMR, COSY and HSQC spectra of compound 
10. Figure S7: 1H, 13C NMR, COSY and HSQC spectra of compound 13. 
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